QLT Completes Sale of Punctal Plug Technology to Mati Therapeutics
April 04, 2013 16:01 ET
|
QLT Inc.
VANCOUVER, British Columbia, April 4, 2013 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company") announced today that it has completed the sale of the Company's punctal plug...
QLT Announces Fourth Quarter and Year End 2012 Results
February 21, 2013 16:05 ET
|
QLT Inc.
VANCOUVER, British Columbia, Feb. 21, 2013 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company") is a biotechnology company dedicated to the development and commercialization...
QLT Board Issues Letter to Shareholders Announcing Corporate Progress and 2013 Objectives
January 28, 2013 08:00 ET
|
QLT Inc.
VANCOUVER, British Columbia, Jan. 28, 2013 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) today issued the following letter to its shareholders outlining the Company's recent progress and its...
QLT Announces Exclusive Option Agreement for Potential Sale of Punctal Plug Delivery System
December 24, 2012 08:00 ET
|
QLT Inc.
VANCOUVER, British Columbia, Dec. 24, 2012 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company") announced today that the Company has entered into an exclusive option agreement...
QLT Announces Reduction in Force
December 06, 2012 08:00 ET
|
QLT Inc.
VANCOUVER, British Columbia, Dec. 6, 2012 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) today announced a 42% reduction of its workforce to better align its resources with the Company's...
QLT Announces Third Quarter 2012 Results
November 07, 2012 07:30 ET
|
QLT Inc.
VANCOUVER, British Columbia, Nov. 7, 2012 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company") is a biotechnology company dedicated to the development and commercialization of...
QLT Shows Positive Efficacy Trends From Data in Plug Combinations in Phase II Studies for Glaucoma Using Latanoprost Punctal Plug Delivery System
October 24, 2012 17:01 ET
|
QLT Inc.
VANCOUVER, British Columbia, Oct. 24, 2012 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) announced that results from two Phase II clinical studies, PPL GLAU 12 and PPL GLAU 13, demonstrate...
QLT Announces Share Repurchase Program
September 27, 2012 08:30 ET
|
QLT Inc.
VANCOUVER, British Columbia, Sept. 27, 2012 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company") announced today that its board of directors has approved a share repurchase...
QLT Announces Sale of Visudyne(R) to Valeant Pharmaceuticals
September 24, 2012 07:30 ET
|
QLT Inc.
VANCOUVER, British Columbia, Sept. 24, 2012 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) announced today that it has completed the sale of the Company's Visudyne® business to Valeant...
QLT Announces Second Quarter 2012 Results
August 02, 2012 08:00 ET
|
QLT Inc.
VANCOUVER, British Columbia, Aug. 2, 2012 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company") is a biotechnology company dedicated to the development and commercialization of...